The QMN Weekly Bulletin

Production at Novartis’ Lincoln, Neb., OTC drug plant has begun to ramp up “line by line, product by product,” but six months of remediation has contributed to flat 2012 sales and a 5 percent drop in operating income compared with last year, company officials say.
Drug Industry Daily